Abivax S.A. American Depositary Receipt (ABVX) Stock Price…

Summary

Abivax S.A., operating as ABIVAX Société Anonyme, is a French pharmaceutical firm focused on the discovery and optimization of therapeutic drugs for inflammatory, infectious, and oncological diseases. A cornerstone of their product pipeline is ABX464, which is currently undergoing Phase IIb clinical trials for ulcerative colitis, Crohn's Disease, and COVID-19. This compound is also being evaluated in Phase IIa studies for rheumatoid arthritis and has successfully completed Phase IIa trials demonstrating viral remission in patients with HIV. Additionally, the company is advancing ABX 196, an immune-boosting candidate, through Phase 1/2 clinical trials targeting hepatocellular cancer. Abivax also conducts research initiatives for conditions like Dengue fever, influenza, and respiratory syncytial virus. The company has secured license agreements with key French scientific bodies, including the National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Founded in 2013, Abivax S.A. maintains its headquarters in Paris, France.

Website

www.abivax.com

Location

Paris, I0, FR

Phone33 1 53 83 08 41

Employees80

CEOMarc de Garidel

Sector

Health Care

Industry

Pharmaceuticals

IPO DateOct 20, 2023

Ask AI

Company overview

Business model, segments, and competition.

Peer comparison

Metrics vs closest competitors.

Guidance & outlook

Forward guidance and assumptions.

Bull vs bear case

Upside drivers and key risks.

Valuation snapshot

Multiples vs history and peers.

Competitive moat

Defensibility and market position.

Management track record

Leadership and capital allocation history.

How it makes money

A short diagram of the business model.

Latest Documents

Mentions in Filings

… tegy, biostatistics and regulatory submissions, including oversight of the pivotal trial design, readout and New Drug Application for CAMZYOS® (mavacamten) at MyoKardia. He currently serves as Chief Strategy Officer of Abivax S.A. Third Quarter 2026 Financial Highlights • Cash Position: As of September 30, 2026, Aardvark had cash, cash equivalents and short-term investments of $60.3 million, compared to $73.9 million as of June 30, 2026. Based …
Aardvark Therapeutics, Inc.Abivax S.A. American Depositary Receipt·EX-99.1 - 8-K - Results of Operations and Financial Condition·Q4 26·13 Nov
… om most other exchange-traded funds (“ETFs”). As a result, the Fund may be riskier than alternatives that do not use leverage because the Fund’s objective is to magnify (200%) the daily performance of the common shares of Abivax SA (The Nasdaq Stock Market LLC (“Nasdaq”): ABVX) (“ABVX”). The return for investors that invest for periods longer or shorter than a single-trading day should not be expected to be 200% of the performance of ABVX for the …
Investment Managers Series Trust IIAbivax S.A. American Depositary Receipt·485APOS - Post-effective amendment (open-end investment companies)·29 Oct·29 Oct
… h companies developing product candidates in Crohn’s disease and ulcerative colitis with a potential anti-fibrotic effect, including Merck & Co., Teva Pharma Ltd. & Sanofi S.A., Roche Holding AG, Pfizer Inc., AbbVie Inc., Abivax SA., Spyre Therapeutics Inc., Caldera Therapeutics Inc., Bionyra Pharma and Xencor Inc. Finally, we will compete with companies developing product candidates in inflammatory bowel disease with gastrointestinal-restricted …
Skye Bioscience, Inc.Abivax S.A. American Depositary Receipt·PRER14A - Preliminary proxy statement (revision)·Q4 26·28 Oct
… h companies developing product candidates in Crohn’s disease and ulcerative colitis with a potential anti-fibrotic effect, including Merck & Co., Teva Pharma Ltd. & Sanofi S.A., Roche Holding AG, Pfizer Inc., AbbVie Inc., Abivax SA., Spyre Therapeutics Inc., Caldera Therapeutics Inc., Bionyra Pharma and Xencor Inc. Finally, we will compete with companies developing product candidates in inflammatory bowel disease with gastrointestinal-restricted …
Skye Bioscience, Inc.Abivax S.A. American Depositary Receipt·PREM14A - Preliminary proxy statement (merger)·Q4 26·26 Oct
… as been evaluated in patients as a component of indigo naturalis and is an endogenously produced molecule. We are aware of several other parties developing drugs with AhR activity in inflammatory bowel disease, including Abivax, Equillium and Dr. Falk Pharma (in partnership with AllianThera Biopharma). Abivax is developing obefazimod, an orally administered, medium-potency systemic AhR agonist that induces upregulation of MiR-124. Obefazimod ha …
ADIAL PHARMACEUTICALS, INC.Abivax S.A. American Depositary Receipt·10-Q/A - AMENDMENT NO. 1 TO FORM 10-Q Q2·Q2 26·20 Oct
… igational agents; includes golimumab, etrasimod, ustekinumab, rosnilimab, MORF-057, PN-943, infliximab, icotrokinra, TYK2 inhibitor, adalimumab, and etrolizumab. Sources: Lancet Gastroenterol Hepatol 2022;7(11):1024–1035; Abivax corporate presentation, March 2023; Abivax phase 3 topline readout, July 2025; obefazimod UEG Week presentation, October 2025; Clin Gastroenterol Hepatol 2026;24(2):525–534; Spyre SKYLINE Part A induction results, April 2 …
Odyssey Therapeutics, Inc.Abivax S.A. American Depositary Receipt·EX-99.2 - 8-K - Regulation FD Disclosure·Q4 26·20 Oct

Key Stats

Trading

Px/Chg 1D$92.88 / -2.33%

Prev Close$114.79

% of 52Wk H79.92%

Avg Volume1.52M

Beta3.54

Mkt Cap6.82B

FD Mkt Cap8.73B

Float

Shrs Out/Float73.43M / 67.11M

Short Float0.07%

Days to Cover1.45

Stock Repurchased$0.00

Current Valuation

EV6.43B

EV/EBITDA0.00

EV/Sales0.00

P/B18.62

P/S0.00

FCF Yield-0.76%

ROE-32.06%

ROA-25.41%

Current Ratio5.97

Estimates

P/E0.00

Est P/E0.00

Est EPS-0.94

Est PEG0.00

Valuation

Metric	5Yr Avg	Jun '24	Sep '25	Sep '26	Oct '26
PRICE-BASED RATIOS
Price / Earnings	-29.79	-3.85	-31.49	-26.81	-56.99
Price / Sales	0.00	0.00	0.00	0.00	0.00
Price / Book Value	43.72	2.90	136.75	16.95	18.27
Price / Free Cash Flow	-69.55	-5.68	-35.87	-108.22	-128.44
ENTERPRISE VALUE METRICS
Enterprise Value	4,856.6	375.4	5,503.1	7,242.8	6,305.2
Enterprise Value / Sales	0.00	0.00	0.00	0.00	0.00
Enterprise Value / EBITDA	-29.11	-2.82	-33.82	-28.29	-51.51
Enterprise Value / EBIT	-28.99	-2.80	-33.59	-28.20	-51.35

Financials

Full Financials

Millions EUR	5Yr CAGR (%)	Dec '21	Dec '22	Dec '23	Dec '24	Dec '25
INCOME STATEMENT
Revenue	—	-	-	-	-	-
Gross Income	—	-45.5	-50.8	-	-	-
EBITDA	67.1%	-38.6	-53.3	-133.2	-162.7	-300.7
EBIT	66.9%	-38.9	-53.8	-133.9	-163.8	-301.8
Net Income	67.7%	-42.5	-60.7	-147.7	-176.2	-336.1
EPS (Diluted)	14%	-2.75	-3.18	-3.43	-2.80	-4.65
BALANCE SHEET
Cash & ST Inv	71.9%	60.7	27.0	261.0	144.2	530.2
Total Assets	52.1%	109.2	75.5	327.1	205.2	584.1
Total Liabilities	11.6%	83.3	68.4	131.1	164.6	129.1
Total Shareholder Equity	104.7%	25.9	7.2	196.0	40.6	455.0
CASH FLOW
Net Operating Cash Flow	35.9%	-45.7	-53.9	-100.0	-154.1	-155.7
Cap Ex	-46.3%	-1.6	-0.3	-0.3	-0.6	-0.1
Free Cash Flow	34.7%	-47.3	-54.3	-100.3	-154.7	-155.8

Enterprise Value Bridge

Millions EUR		13 Nov '26
Price (As of 13 Nov '26)		88.00
Basic Shares		73.43
Market Cap		6,462.1
Diluted Shares		79.65
Fully Diluted Shares Outstanding		79.65
Fully Diluted Market Cap		7,009.0
+Consolidated Debt		1.2
−In-the-Money Convertible Debt		—
+Capital Leases		1.2
+Operating Leases		—
−Cash & Equivalents		-388.0
−Short-term Investments		-22.7
+Total Preferred		-
−In-the-Money Convertible Preferred		—
−Investments in Unconsolidated Subs		—
+Non-Controlling Interest		-
+Pension Liabilities		—
Enterprise Value		6,075.3

Related companies